Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lyell Immunopharma, Inc. - Common Stock
(NQ:
LYEL
)
16.37
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lyell Immunopharma, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
What's going on in today's session
↗
June 04, 2025
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
May 13, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
May 01, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
↗
November 12, 2024
Via
Benzinga
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
April 15, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
What's going on in today's session
↗
March 19, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
March 19, 2025
Via
Benzinga
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
March 11, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
February 18, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
January 09, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
December 09, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
November 07, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
October 31, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
↗
October 30, 2024
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.
Via
Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
↗
October 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 24, 2024
Via
Benzinga
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
October 24, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 04, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
September 24, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in September Investor Conferences
August 28, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
↗
August 19, 2024
Via
Benzinga
LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q2 2024
↗
August 08, 2024
LYEL stock results show that Lyell Immunopharma beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
August 07, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
3 Biotech Stocks to Sell in August Before They Crash & Burn
↗
August 06, 2024
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains.
Via
InvestorPlace
Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
↗
June 26, 2024
Lyell Immunopharma shares fell following the release of initial clinical data from its Phase 1 trial of LYL797, a reprogrammed CAR T-cell product. The company reported some severe cases reported in...
Via
Benzinga
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
June 26, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
June 03, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
May 07, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q1 2024
↗
May 06, 2024
LYEL stock results show that Lyell Immunopharma beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
